鳞状细胞癌抗原、神经元特异性烯醇化酶和细胞角蛋白19片段检测与小细胞肺癌预后的相关性研究

The research of the relativity between the prognosis of the small cell lung cancer and the examination of squamous cell carcinoma antigen,neuron specific enolase and CYFRA21-1

目的通过检测小细胞肺癌患者治疗后的鳞状细胞癌抗原(SCC)、神经元特异性烯醇化酶(NSE)以及细胞角蛋白19片段(CYFRA21-1)指标,预测小细胞肺癌的复发和转移,为此类患者的术后巩固治疗提供临床依据。方法用酶联免疫吸附试验(ELISA)测定75例小细胞肺癌患者的血清SCC、NSE和CYFRA21-1,并计算三者与肿瘤预后的相关性。结果在45例复发患者的样本中,NSE升高35例,CYFRA21-1升高29例,另有7例样本出现SCC升高,并且在手术后半年尤为明显。结论小细胞肺癌患者治疗后,NSE和CYFRA21-1的上升与小细胞肺癌的复发和转移密切相关,建议作为患者肿瘤随访的检查指标。

Objective To investigate the level of the squamous cell carcinoma antigen（ SCC）, neuron specific enolase（NSE） and cytokeratin 19 fragment（ CYFRA21-1 ） of the patients who had the operation for lung cancer, and the relationship with the metastasis and prognosis was evaluated. Methods The serum samples from 75 patients who suffered from the small cell lung cancer were examined by the enzyme-linked immunosorbent assay（ELISA） for SCC, NSE and CYFRA21-1. The relationship among them was analysed by statistics method. Results In 45 samples of the recurrent patients, 35 cases showed SCC antigen levels above the upper limit of normal, 29 cases showed CYFRA21-1 antigen levels above the upper limit, and 7 cases with the rising of the NSE. This situation was more obvious in six months after excision of the tumour. Conclusions After the treatment of the small cell lung cancer, there is tight relationship between the rising of the NSE and CYFRA21-1 and the metastasis and the recurrence of the tumour. So these two items could be used as the follow-up markers for the patient.